Duchenne Muscular Dystrophy
Emflaza is approved for the treatment of Duchenne muscular dystrophy regardless of genetic etiology.
Patients who received ACE inhibitors showed a slower progression of myocardial fibrosis and fewer cardiovascular events.
Eteplirsen is the first drug approved in the US for the treatment of DMD.
Over 52 weeks, patients taking deflazacort experienced improved muscle strength and less weight gain compared with prednisone.
Deflazacort is intended to help improve muscle strength and other functional outcomes in DMD regardless of genetic etiology.
The DMD space is becoming increasingly crowded as the FDA works to identify a drug worth approving.
This is the second extension requested by the FDA.
The panel took a similar stance in the fall when it did not recommend Biomarin's drisapersen for the treatment of DMD.
After a lukewarm review, the FDA has officially denied the NDA for drisapersen.
Translarna (ataluren) is for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).
Researchers recommend that follow-up protocols be developed for those with elevated CK but negative DMD gene testing.
The committee cited a lack of consistent clinical trial results as well as concerns over serious adverse events.
Researchers have linked the Jagged1 gene to a much milder form of muscular dystrophy in golden retrievers.
The FDA is set to make a decision on the NDA by late February, 2016.
A deflazacort regimen appeared to slow loss of ambulation, but not without several side effects.
The conditions are similar, but differ in rate of progression and age of onset.
Neurology Advisor Articles
- Brainstem Damage in Epilepsy May Be Biomarker for Increased SUDEP Risk
- Increased Epilepsy Risk Identified in Multiple Sclerosis
- Distinct Clinical Characteristics Associated With Subarachnoid Hemorrhage
- Managing Chronic Pain Associated With Traumatic Brain Injury
- Prognostic Significance of Weight Loss in Patients With Early Parkinsonism
- Coffee Consumption May Decrease Stroke Risk
- When and How to Approach Driving Cessation in Patients With Dementia
- NBT System Gets FDA Clearance for Depression Treatment
- Erenumab, Fremanezumab Reduce Migraine Frequency, Burden
- Some Antiepileptic Drugs Associated With Increased Risk for Toxic Epidermal Necrolysis
- McDonald Criteria Update: Further Distinction Between Relapsing-Remitting, Primary-Progressive MS
- Initial Treatment With Ethosuximide Improves Behavioral Outcomes in Childhood Absence Epilepsy
- Bivacizumab Wins Full FDA Approval for Glioblastoma Treatment
- Men With Parkinson Disease More Likely to Have Caregiver
- Diet Linked to Multiple Sclerosis Disability, Diseases Severity